COST-UTILITY ANALYSIS OF 10-AND 13-VALENT PNEUMOCOCOCCAL CONJUGATE VACCINES IN THE PHILIPPINES

被引：0
|
作者：
Haasis, M. A. [1 ]
Ceria, J. A. [1 ]
机构：
[1] Dept Hlth, Manila, Philippines
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN26
引用
收藏
页码：A807 / A807
页数：1
相关论文
共 50 条
  • [21] Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
    Hanquet, Germaine
    Krizova, Pavla
    Dalby, Tina
    Ladhani, Shamez N.
    Nuorti, J. Pekka
    Danis, Kostas
    Mereckiene, Jolita
    Knol, Mirjam J.
    Winje, Brita A.
    Ciruela, Pilar
    de Miguel, Sara
    Eugenia Portillo, Maria
    MacDonald, Laura
    Morfeldt, Eva
    Kozakova, Jana
    Valentiner-Branth, Palle
    Fry, Norman K.
    Rinta-Kokko, Hanna
    Varon, Emmanuelle
    Corcoran, Mary
    van der Ende, Arie
    Vestrheim, Didrik F.
    Munoz-Almagro, Carmen
    Sanz, Juan-Carlos
    Castilla, Jesus
    Smith, Andrew
    Henriques-Normark, Birgitta
    Colzani, Edoardo
    Pastore-Celentano, Lucia
    Savulescu, Camelia
    EMERGING INFECTIOUS DISEASES, 2022, 28 (01) : 127 - 138
  • [22] Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine
    Ceyhan, Mehmet
    JOURNAL OF PEDIATRIC INFECTION, 2011, 5 (02): : 68 - 73
  • [23] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Reply
    Naucler, Pontus
    Galanis, Ilias
    Morfeldt, Eva
    Darenberg, Jessica
    Ortqvist, Ake
    Henriques-Normark, Birgitta
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1642 - 1643
  • [24] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN COLOMBIA
    Coronel, W.
    Jaramillo, J.
    Caceres, H. A.
    Riveros, L.
    VALUE IN HEALTH, 2011, 14 (03) : A117 - A117
  • [25] Impact of 10-and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012
    Weiss, S.
    Falkenhorst, G.
    van der Linden, M.
    Imoehl, M.
    von Kries, R.
    EUROSURVEILLANCE, 2015, 20 (10):
  • [26] The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis
    Alicino, Cristiano
    Paganino, Chiara
    Orsi, Andrea
    Astengo, Matteo
    Trucchi, Cecilia
    Icardi, Giancarlo
    Ansaldi, Filippo
    VACCINE, 2017, 35 (43) : 5776 - 5785
  • [27] Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines
    Gessner, Bradford D.
    Sings, Heather L.
    Jodar, Luis
    LANCET INFECTIOUS DISEASES, 2019, 19 (07): : 692 - 693
  • [28] The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ?
    Madhi, Shabir A.
    Goldblatt, David
    LANCET INFECTIOUS DISEASES, 2019, 19 (05): : 453 - 454
  • [29] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN BOGOTA, COLOMBIA
    Torres, C.
    Jaramillo, J.
    Coronell, W.
    Gutierrez, M., V
    Caceres, H. A.
    VALUE IN HEALTH, 2011, 14 (07) : A538 - A538
  • [30] COST-EFFECTIVENESS OF SWITCHING FROM THE 10-VALENT TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWEDEN
    Wasserman, M.
    Dorange, A. C.
    Palmborg, A.
    McDade, C.
    Wilson, M.
    Horn, E.
    VALUE IN HEALTH, 2022, 25 (01) : S110 - S110
12345